$3
+0.09
(+3.09%)▲
4.67%
Downside
Day's Volatility :5.92%
Upside
1.32%
33.0%
Downside
52 Weeks Volatility :65.22%
Upside
48.1%
Period | Allogene Therapeutics, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 0.69% | 6.5% | 0.0% |
6 Months | -10.19% | 7.1% | 0.0% |
1 Year | -42.49% | 9.8% | 0.0% |
3 Years | -86.59% | 14.2% | -20.2% |
Market Capitalization | 607.6M |
Book Value | $2.71 |
Earnings Per Share (EPS) | -1.78 |
Wall Street Target Price | 11.51 |
Profit Margin | 0.0% |
Operating Margin TTM | -315927.27% |
Return On Assets TTM | -26.71% |
Return On Equity TTM | -55.48% |
Revenue TTM | 87.0K |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -26.700000000000003% |
Gross Profit TTM | 243.0K |
EBITDA | -270.7M |
Diluted Eps TTM | -1.78 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.52 |
EPS Estimate Next Year | -1.57 |
EPS Estimate Current Quarter | -0.41 |
EPS Estimate Next Quarter | -0.4 |
What analysts predicted
Upside of 283.67%
Sell
Neutral
Buy
Allogene Therapeutics, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Allogene Therapeutics, Inc. | 24.36% | -10.19% | -42.49% | -86.59% | -90.09% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Allogene Therapeutics, Inc. | NA | NA | NA | -1.52 | -0.55 | -0.27 | NA | 2.71 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Allogene Therapeutics, Inc. | Buy | $607.6M | -90.09% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Allogene Therapeutics, Inc.
Revenue is up for the last 2 quarters, 21.0K → 22.0K (in $), with an average increase of 4.6% per quarter
Netprofit is up for the last 2 quarters, -85.77M → -65.0M (in $), with an average increase of 32.0% per quarter
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 104.1%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 273.1%
FMR Inc
TPG GP A, LLC
BlackRock Inc
State Street Corporation
Vanguard Group Inc
PRIMECAP Management Company
allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-positioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. this approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le
Organization | Allogene Therapeutics, Inc. |
Employees | 232 |
CEO | Dr. Arie S. Belldegrun F.A.C.S., M.D. |
Industry | Health Technology |
A Spac I Acquisition Corp
$3.00
+3.09%
Keyarch Acquisition Corp
$3.00
+3.09%
Connexa Sports Technologies Inc
$3.00
+3.09%
Us Value Etf
$3.00
+3.09%
First Wave Biopharma Inc
$3.00
+3.09%
Global X Msci Next Emerging
$3.00
+3.09%
Fat Projects Acquisition Corp
$3.00
+3.09%
Capital Link Global Fintech
$3.00
+3.09%
Applied Uv Inc
$3.00
+3.09%